Addex Therapeutics grants Hill 943K stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Addex Therapeutics Ltd. (ADXN) director Raymond George Hill was granted 942,854 stock options on November 11, 2026. Each option gives the right to purchase one ADXN share at an exercise price of $0.0260 per share. The options vest in equal monthly installments over four years beginning on the exercisable date and expire November 10, 2036. Following the award, Hill reported holding 1,215,961 stock options.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 942,854 | $0.00 | $0.00 |
Footnotes (2)
- F1. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.
- F2. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.1995 per CHF 1.00 as of November 11, 2026.
Key Figures
Key Terms
Stock-option (Right to Buy) technical
exercise price financial
exercisable date technical
equal monthly installments technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did ADXN director Raymond George Hill receive?
AI-generated analysis. How Rhea-AI works. Not financial advice.